" class="no-js "lang="en-US"> Boehringer Ingelheim - Medtech Alert
Sunday, September 07, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Boehringer Ingelheim | Pharmtech Focus

Boehringer Ingelheim

About Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.

Related Story

Diseases

 Healthy.io Announces Collaboration with Boehringer Ingelheim to Increase Access to Testing for Kidney Disease | MTA

Healthy.io Announces Collaboration with Boehringer Ingelheim to Increase Access to Testing for Kidney Disease

May 10 2023

Healthy.io, the global leader in transforming the smartphone camera into a medical device, today announced […]

Diseases

 US FDA Accepts Supplemental New Drug Application for Jardiance® for Adults with Chronic Kidney Disease | PTF

US FDA Accepts Supplemental New Drug Application for Jardiance® for Adults with Chronic Kidney Disease

January 20 2023

The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) […]

News

 Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies | PTF

Boehringer Ingelheim and 3T Biosciences Join Forces to Develop Next-Generation Cancer Immunotherapies

January 9 2023

Boehringer Ingelheim and 3T Biosciences today announced they have entered into a strategic collaboration and licensing […]

Industry News

 ArisGlobal Acquires Boehringer Ingelheim’s Signal Analytics Engine

ArisGlobal Acquires Boehringer Ingelheim’s Signal Analytics Engine, Bringing Enhanced and Unmatched Pharmacovigilance Capabilities to Life Sciences Industry

May 12 2022

ArisGlobal, the global market leader in drug safety solutions worldwide, and Boehringer Ingelheim, a leading […]